Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.71
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb);...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Data is available to registered users only
Buy
Sell